NAD+: Research Overview

The short version

NAD+ (nicotinamide adenine dinucleotide) is not a peptide — it is an endogenous coenzyme present in every cell, essential for generating ATP in glycolysis and the TCA cycle, and a required substrate for signaling enzymes (sirtuins, PARPs, CD38) that govern DNA repair and gene regulation. NAD+ levels in tissues decline with age, partly because the NAD-consuming enzyme CD38 increases with age and inflammation ^[31].

The rationale for supplementation is to restore declining NAD+ through its precursors, NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Human trials demonstrate that oral NMN and NR reliably raise blood NAD+ ^[29][32]. A 2023 multicenter double-blind RCT of NMN improved walking distance and quality-of-life scores in middle-aged adults ^[29]; a 2021 Science paper found NMN improved muscle insulin sensitivity in prediabetic women ^[30]. A 2025 Nature Metabolism review concludes human trials to date have shown "limited efficacy" and that translation to hard clinical endpoints remains unproven ^[28]. This page covers the evidence — not dosing advice, and with the NAD-vs-precursor distinction preserved throughout.

What it is

NAD+ is a dinucleotide of nicotinamide mononucleotide and adenosine monophosphate joined by two bridging phosphate groups. The pyridine nicotinamide ring accepts electrons during cellular metabolism, cycling between the oxidized (NAD+) and reduced (NADH) forms. Molecular formula C21H27N7O14P2.

The precursor distinction matters practically and chemically: oral NAD+ itself is poorly absorbed intact by most cells — the molecule is too large and hydrophilic to cross cell membranes easily. NMN and NR are smaller precursors that enter cells more readily and are converted to NAD+ intracellularly via salvage pathways. Most experts consider NMN or NR the rational oral approach; plain "NAD+ capsules" may largely degrade before reaching the intracellular NAD+ pool.

IV-infused NAD+ bypasses this limitation but is rapidly cleared from plasma, requires clinical administration, and can cause chest or abdominal discomfort, flushing, and nausea if infused too quickly. Compounded injectable NAD+ has been subject to FDA Class I recall for elevated bacterial endotoxin — a serious contamination risk.

How it works

NAD+ serves two major roles in cells ^[31]:

Redox carrier: In glycolysis, the TCA cycle, and oxidative phosphorylation, NAD+ accepts electrons (becoming NADH), which are then donated to mitochondrial Complex I to drive ATP synthesis. This is the core energy-production function.

Signaling substrate (consumed, not recycled): Three enzyme families use NAD+ as a co-substrate and consume it in the process:

• Sirtuins (SIRT1-7): NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis, DNA repair, and metabolic adaptation. SIRT1 and SIRT3 are most studied for longevity biology.
• PARPs (chiefly PARP1): Consume NAD+ to repair DNA strand breaks; sustained DNA damage or genotoxic stress can deplete NAD+ reserves via PARP activation.
• CD38/CD157: NAD-consuming ectoenzymes that rise with age and inflammation, consuming NAD+ faster and competing with sirtuins for the same pool.

The rationale for NAD+ supplementation is that as tissue NAD+ falls with age, sirtuin and PARP activity is impaired, reducing the cell's capacity to respond to metabolic stress and DNA damage.

What the research shows

NMN in middle-aged adults (2023 multicenter double-blind RCT): Oral NMN 300–900 mg/day for 60 days dose-dependently raised blood NAD+ (p≤0.001 at days 30 and 60 across all NMN groups vs placebo). Walking distance and quality-of-life scores improved at the 600 mg/day optimal dose. No safety issues at any dose. Biological age measure did not increase ^[29].

NMN in prediabetic postmenopausal women (2021, Science): 250 mg/day for 10 weeks improved muscle insulin sensitivity (assessed by hyperinsulinemic-euglycemic clamp) and remodeled insulin signaling in skeletal muscle. No change in body composition or HbA1c ^[30].

NR dose-escalation study (2019, healthy overweight adults): NR at 100–1000 mg/day for 8 weeks dose-dependently raised whole-blood NAD+ by 22%, 51%, and 142% respectively. No flushing, no significant adverse-event differences from placebo. NR did not elevate LDL or disrupt one-carbon metabolism ^[32].

2025 Nature Metabolism review: Concludes that human trials have shown limited efficacy, age-related NAD+ decline has been consistently observed only in a limited number of human studies, tissue-specific NAD+ dynamics remain sparse, and more clinical studies of systemic and tissue-specific NAD+ metabolism are needed rather than reliance on rodent extrapolation ^[28].

Foundational biology review (2021, Nature Reviews Molecular Cell Biology): Frames declining NAD+ with age as linked to metabolic dysfunction and disease susceptibility across model organisms and humans, identifies the major competing NAD-consuming enzymes, and frames NAD+ restoration as a candidate strategy against age-related disease ^[31].

Reported effects, cautions, and safety

What people report with NMN/NR supplementation (anecdotal, not clinical evidence): Common reported benefits include increased energy, better sleep, improved mental clarity, and a general sense of well-being — mostly anecdotal and difficult to separate from placebo. Some report tangible improvements in exercise recovery. Others report nothing at all. GI symptoms (nausea, loose stools) are occasionally reported at higher doses. Flushing is rare with NR (unlike plain nicotinamide) but can occur.

Safety cautions and controversies:

• Oral NAD+ capsules may be less effective than NMN or NR because of poor cellular uptake of intact NAD+.
• IV NAD+ infusions carry unique risks: too-fast infusion causes chest tightness, abdominal discomfort, and nausea; compounded IV formulations have been recalled for endotoxin contamination by the FDA.
• A theoretical concern exists that boosting NAD+ could support the metabolism of existing cancers, since NAD+ is essential for proliferating cells; the evidence is context-dependent, but caution is appropriate in oncology populations.
• NMN's regulatory status as a dietary supplement is contested: the FDA has asserted that NMN was investigated as a drug prior to being marketed as a supplement, which may exclude it from the dietary-supplement definition in the US. The marketplace situation is unresolved.
• Long-term human safety data for sustained high-dose supplementation are not available.
• WADA: NAD+ and its precursors are not prohibited.

Where it fits in the research landscape

NAD+ sits at the intersection of basic metabolism and longevity biology — the only compound on this desk that is not a peptide, and the only one already present in every cell in the body. Its precursors (NMN, NR) have more and better human clinical evidence than most research peptides, but the hard clinical endpoints — disease prevention, longevity extension, meaningful organ-function improvement — remain unproven as of 2025 ^[28].

The narrative around NAD+ has outrun the evidence in ways familiar from other longevity fields: rodent studies look dramatic, early human trials look promising on biomarker endpoints, and the translation to hard clinical outcomes in large trials is still waiting to be established. The 2025 Nature Metabolism review is the most authoritative current synthesis of where the human evidence actually is.